New vaccine combo takes on tough cancers
NCT ID NCT06411691
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 4 times
Summary
This early-stage study tests a cancer vaccine that targets a common mutated protein (KRAS) combined with two immunotherapy drugs (balstilimab and botensilimab) in people with advanced colorectal or pancreatic cancer that has spread. The goal is to see if the combination can shrink tumors or slow disease progression. About 54 adults whose cancer has not responded to standard chemotherapy will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?